Castle Biosciences completes Cernostics acquistion

LabPulse.com staff writers
Dec 5, 2021
2020 07 02 23 31 0378 Handshake Meeting 400

Castle Biosciences has completed its purchase of Cernostics for $30 million. The company will pay up to $50 million more if Cernostics fulfills particular milestones in 2022.

The acquisition expands Castle's offerings to include Cernostics' TissueCypher Barrett's Esophagus Assay, a test that predicts future development of high-grade dysplasia and/or esophageal cancer in patients with Barrett's esophagus, it said.

Latest in Esophageal Cancer
Cancer Cell Microenvironment Social
At USCAP 2023, ProPhase Labs to present data about esophageal cancer screening test
March 13, 2023
Dna Cancer Cell Social
Study evaluates Prophase Labs test for esophageal cancer
February 16, 2023
Quality Check Mark Social
Lucid Diagnostics study demonstrates esophageal cell sampling in office setting
December 1, 2022
2021 04 27 15 25 5437 Pathology Digital Workstation Microscope 400
CDx Diagnostics, Avalon ink in-network lab agreement
June 13, 2022
Related Stories
2021 12 30 00 31 3981 Business Graph Money Stocks 400
Skin Cancer
Castle Biosciences posts revenue surge, lower net loss in Q2
2020 03 25 23 27 0591 Hands Shaking Deal 400
Bipolar Disorder
Castle Biosciences completes $65M AltheaDx acquisition
2019 05 02 23 38 2538 Check Mark 400
Esophageal Cancer
Castle's esophagus test nabs ADLT status
2019 07 11 21 34 8877 Melanoma 400
Pathology, histology
Castle touts study results for DecisionDx technologies
More in Esophageal Cancer
At USCAP 2023, ProPhase Labs to present data about esophageal cancer screening test
The upcoming presentation in New Orleans is scheduled for March 14 and entitled "Targeted Mass Spectrometry of Barrett's Esophagus Reveals High-Fidelity Combinatorial Molecular Correlates."
March 13, 2023
Cancer Cell Microenvironment Social
Study evaluates Prophase Labs test for esophageal cancer
The study authors note that early detection, especially through noninvasive biomarker-based tests such as Prophase Labs' BE-Smart test, is critical to improving outcomes for esophageal cancer.
February 16, 2023
Dna Cancer Cell Social
Lucid Diagnostics study demonstrates esophageal cell sampling in office setting
More than 90% of samples collected yielded DNA to perform molecular biomarker testing using the company’s EsoGuard Esophageal DNA test.
December 1, 2022
Quality Check Mark Social
CDx Diagnostics, Avalon ink in-network lab agreement
The agreement makes CDx's diagnostic platform, WATS3D, available to the 565,000 members of BCBS of South Carolina, including all of its commercial and Medicare Advantage plans.
June 13, 2022
2021 04 27 15 25 5437 Pathology Digital Workstation Microscope 400
Lucid’s LucidDx Labs signs deal with MediNcrease
This is Lucid's first agreement with a commercial payer. The deal will provide in-network access and payment for Lucid's EsoGuard DNA test to those insured by MediNcrease. The health insurance plan currently provides coverage to 8 million people.
May 8, 2022
2020 03 16 19 06 1700 Insurance Coverage 400
Lucid promotes new guideline from ACG on esophageal cancer
The new guidelines include a reference to screening for esophageal cancer using Lucid's EsoGuard DNA test on samples collected with its EsoCheck Cell Collection device, it said.
April 3, 2022
2019 04 05 16 58 5171 Cancer Cell 400
Castle's esophagus test nabs ADLT status
The test aims to predict whether patients with Barrett's esophagus will develop esophageal cancer or high-grade dysplasia. The status was effective March 24.
March 29, 2022
2019 05 02 23 38 2538 Check Mark 400
Lucid launches 3 new test centers
The test centers are staffed with Lucid-employed nurse practitioners who use Lucid's EsoCheck cell collection device to collect surface esophageal cells. Then, the cells undergo Lucid's EsoGuard DNA esophageal test.
March 22, 2022
2022 03 23 21 50 7128 Stomach And Medical Icon2 400
Agilent secures expanded CE Mark for cancer assay
The test may now be used to identify esophageal cancer patients eligible for treatment with Keytruda, a monoclonal antibody developed by Merck that boosts the body's ability to fight cancer cells.
August 22, 2021
2020 04 14 17 10 6379 Test Tubes Rd Lab 400
Page 1 of 1